#United States #cancer detection #HT Vet #VISTA iQ #Hillside, NJ

Transforming Veterinary Care with VISTA iQ™

In the pet healthcare realm, early detection of cancer can be a game changer. HT Vet, a pioneering veterinary health technology company, has introduced the VISTA iQ™, the first AI-powered, non-invasive cancer detection device specifically designed for lumps on dogs. This innovation holds the potential to not only change the way veterinarians diagnose cancer but also significantly boost revenue for veterinary clinics.

The VISTA iQ™, which serves as an advanced version of the original HT Vista scanner, harnesses cutting-edge technology. By utilizing heat diffusion analysis alongside integrated AI, the scanner quickly assesses lumps and bumps in dogs, providing vital data for oncological assessments. This method is not just a leap in technology, it represents a shift in veterinary practice that emphasizes speed and efficiency, allowing clinics to offer vital diagnostics seamlessly during initial visits.

According to the 2025 Veterinary Industry Benchmark Report by iVET360, there’s a pressing need for clinics to adapt to the changing landscape of veterinary care. With traditional diagnostics leading to high costs and low visit volumes, HT Vet's VISTA iQ™ answers this call, promoting affordable yet advanced care options. The initial response has been robust, with hundreds of clinics either pre-ordering the device or expressing interest due to its promise of quick, reliable cancer diagnostics, which can save lives and improve patient outcomes.

CEO Shani Toledano emphasizes the importance of providing essential services that prioritize patient health. “Clinics must distinguish between optional services and those that are critical for pet health,” Toledano stated. The VISTA iQ™ not only enhances clinic offerings but also aims to reduce the historically common worrisome “wait and see” approach that often leads to poor outcomes for pets.

The statistics are staggering. More than 19 million veterinary visits in North America involve lumps and bumps, yet a mere 39% of these cases undergo fine-needle aspirates (FNAs), with less than half proceeding to reference labs. This gap represents a significant delay in cancer detection, which the VISTA iQ™ aims to close. By providing preliminary diagnostic results within a mere 40 seconds, clinics can now facilitate quicker decisions regarding patient care, ensuring that cases needing urgent intervention are swiftly addressed.

Veterinary oncologist Dr. Craig Clifford highlights the critical nature of early detection. He points out that “if a Mast Cell Tumor or Soft Tissue Sarcoma is detected early, survival times can extend significantly beyond what can be achieved after a delay.” The VISTA iQ™ fundamentally alters how clinics address these health concerns, fostering an environment that prioritizes proactive care.

The financial benefits of adopting the VISTA iQ™ are considerable. Clinics can expect a notable increase in surgery conversion rates from FNAs, rising from 15% to 40%. This improvement translates to an additional $130,000 in annual revenue per clinic, while diagnostic labs can see benefits exceeding $30,000 annually. With around 30,000 veterinary clinics across the U.S., the total market opportunity significantly exceeds $900 million, showcasing an expansive potential for growth and profitability.

The VISTA iQ™ is now available through an annual subscription model, effectively positioning itself as a primary tool for veterinary cancer diagnostics. With over 35,000 scans performed since its commercialization in 2023, this technology is set not only to redefine how clinics operate but also to provide a clear competitive edge in a bustling market.

HT Vet plans to showcase the VISTA iQ™ at the VMX 2026 event in Orlando, Florida, which runs from January 17-21, marking its official debut to the larger veterinary community. The response from industry leaders and veterinarians is already significant, promising to make the VISTA iQ™ a staple in veterinary diagnostic procedures while ensuring that veterinarians can provide more timely and effective care to their patients.

In conclusion, the introduction of VISTA iQ™ does not merely serve as a diagnostic tool; it is a momentous step towards revolutionizing pet healthcare, fostering an ecosystem where early detection leads to better health outcomes and sustainability in veterinary practice. For anyone in veterinary medicine, the VISTA iQ™ offers not just a solution for cancer diagnosis but an avenue for enhancing overall clinic performance and client satisfaction.

For further details, you can visit HT Vet's website.